Form 4: Balchem SVP Frederic Boned Reports Equity Transactions

Balchem Corporation's SVP Frederic Boned reported recent equity transactions, including restricted stock grants, performance unit vesting, and stock option awards, alongside tax-related share dispositions.

Summary

• Frederic Boned, SVP/GM, Human Nutrition & Health at Balchem Corp (BCPC), reported several equity transactions on February 11, 2026, and February 12, 2026.
• Acquired 2,870 shares of common stock as restricted stock, which vests over a three-year period (25% on the first anniversary, 25% on the second anniversary, and 50% on the third anniversary of the grant date).
• Acquired 2,247 shares of common stock from the vesting of performance stock units for the 2023-2025 performance period, which included 37 dividend equivalent shares.
• Disposed of 1,151 shares of common stock at a price of $178.68 to cover tax requirements due upon the vesting of performance stock units on February 11, 2026.
• Disposed of 203 shares of common stock at a price of $177.49 to cover withholding taxes due upon the vesting of restricted shares granted on February 12, 2025.
• Acquired 10,500 stock options with an exercise price of $178.68, which vest 20% in Year 1, 40% in Year 2, and 40% in Year 3, and expire on February 11, 2036.
• Following these transactions, beneficial ownership of common stock is 8,978 shares held directly and 441 shares held indirectly through a 401(k) Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive alignment and performance, as Frederic Boned received significant equity awards and achieved performance targets, although some shares were sold for tax purposes, which is a standard practice.

Positives

• Frederic Boned acquired 2,870 shares of restricted common stock, aligning his interests with the company's long-term performance.
• Boned received 2,247 shares from the vesting of performance stock units, indicating the achievement of performance targets for the 2023-2025 period.
• Boned was granted 10,500 stock options, providing future upside potential tied to stock price appreciation and further aligning his incentives with shareholder value.

Negatives

• Disposed of 1,151 shares of common stock at $178.68 to cover tax obligations related to performance stock unit vesting.
• Disposed of 203 shares of common stock at $177.49 to cover withholding taxes upon the vesting of restricted shares.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that these transactions are routine executive compensation events, reflecting standard practices for aligning management incentives with shareholder interests through equity awards. The vesting of performance units suggests the company met specific operational or financial goals during the 2023-2025 period.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with long-term shareholder value through significant equity awards.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Vesting of the 2,870 restricted shares will occur over the next three years, with 25% on the first anniversary, 25% on the second, and 50% on the third.
• The 10,500 stock options will vest over three years, with 20% in Year 1, 40% in Year 2, and 40% in Year 3.

Key Dates

Recommendation

This Form 4 details routine executive compensation and tax-related transactions, which do not provide new fundamental information to warrant a change in investment recommendation. The equity awards align executive interests with shareholders, but the tax-related sales are standard practice and not indicative of a change in sentiment regarding the company's prospects.

Keywords

Balchem, BCPC, Form 4, insider trading, equity compensation, stock options, restricted stock, performance stock units, executive compensation